Policy change and the National Essential Medicines List development process in Brazil between 2000 and 2014: has the Essential Medicine concept been abandoned?

Claudia Garcia Serpa Osorio-de-Castro, Thiago Botelho Azeredo, Vera Lúcia Edais Pepe, Luciane Cruz Lopes, Sueli Yamauti, Brian Godman, Lars L Gustafsson

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence-based editions were produced, building on the essential medicines concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the paper is to report efforts to develop Brazil´s national EML, policy changes from 2000 to 2014, discussing results, challenges, and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm-changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference, (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.
LanguageEnglish
JournalBasic and Clinical Pharmacology and Toxicology
Early online date8 Nov 2017
DOIs
StateE-pub ahead of print - 8 Nov 2017

Fingerprint

Legislation
Medicine
Brazil
Government Financing
History of Medicine
Health
Jurisprudence
Physicians
Education
Substitution reactions
History
Therapeutics

Keywords

  • essential medicines list
  • pharmaceutical policy
  • Brazil

Cite this

Osorio-de-Castro, Claudia Garcia Serpa ; Botelho Azeredo, Thiago ; Pepe, Vera Lúcia Edais ; Cruz Lopes, Luciane ; Yamauti, Sueli ; Godman, Brian ; Gustafsson, Lars L. / Policy change and the National Essential Medicines List development process in Brazil between 2000 and 2014 : has the Essential Medicine concept been abandoned?. In: Basic and Clinical Pharmacology and Toxicology . 2017
@article{f9d55b3660ad4347a4f94b5c1787f4d0,
title = "Policy change and the National Essential Medicines List development process in Brazil between 2000 and 2014: has the Essential Medicine concept been abandoned?",
abstract = "Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence-based editions were produced, building on the essential medicines concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the paper is to report efforts to develop Brazil´s national EML, policy changes from 2000 to 2014, discussing results, challenges, and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm-changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference, (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.",
keywords = "essential medicines list, pharmaceutical policy, Brazil",
author = "Osorio-de-Castro, {Claudia Garcia Serpa} and {Botelho Azeredo}, Thiago and Pepe, {Vera L{\'u}cia Edais} and {Cruz Lopes}, Luciane and Sueli Yamauti and Brian Godman and Gustafsson, {Lars L}",
year = "2017",
month = "11",
day = "8",
doi = "10.1111/bcpt.12932",
language = "English",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",

}

Policy change and the National Essential Medicines List development process in Brazil between 2000 and 2014 : has the Essential Medicine concept been abandoned? / Osorio-de-Castro, Claudia Garcia Serpa ; Botelho Azeredo, Thiago; Pepe, Vera Lúcia Edais; Cruz Lopes, Luciane; Yamauti, Sueli; Godman, Brian; Gustafsson, Lars L.

In: Basic and Clinical Pharmacology and Toxicology , 08.11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Policy change and the National Essential Medicines List development process in Brazil between 2000 and 2014

T2 - Basic and Clinical Pharmacology and Toxicology

AU - Osorio-de-Castro,Claudia Garcia Serpa

AU - Botelho Azeredo,Thiago

AU - Pepe,Vera Lúcia Edais

AU - Cruz Lopes,Luciane

AU - Yamauti,Sueli

AU - Godman,Brian

AU - Gustafsson,Lars L

PY - 2017/11/8

Y1 - 2017/11/8

N2 - Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence-based editions were produced, building on the essential medicines concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the paper is to report efforts to develop Brazil´s national EML, policy changes from 2000 to 2014, discussing results, challenges, and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm-changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference, (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.

AB - Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence-based editions were produced, building on the essential medicines concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the paper is to report efforts to develop Brazil´s national EML, policy changes from 2000 to 2014, discussing results, challenges, and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm-changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference, (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.

KW - essential medicines list

KW - pharmaceutical policy

KW - Brazil

UR - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1742-7843

U2 - 10.1111/bcpt.12932

DO - 10.1111/bcpt.12932

M3 - Article

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

ER -